Fluvastatin Sodium
FDA-approved product (capsule, oral), marketed as Fluvastatin Sodium, Lescol, Lescol Xl.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Familial hypercholesterolemia
- Hypercholesterolemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hmg coa reductase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fluvastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy
NCT01634906 · start 2012-07
Registered record
- Registry ID
- NCT01634906
- Conditions
- Hyperlipidemia; Atherosclerosis
- Interventions
- Temporary discontinuation of statin therapy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-07
- Completion
- 2013-03
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperlipidemia; AtherosclerosisInterventionTemporary discontinuation of statin therapyPhaseNot applicableRegistry statusCompletedHigh Potency Statins and the Risk of Diabetes
NCT02518503 · start 2012-07
Registered record
- Registry ID
- NCT02518503
- Conditions
- Diabetes Mellitus, Type 2; Cardiovascular Disease
- Interventions
- Rosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin; Pravastatin; Lovastatin; Rosuvastatin (<10mg); Atorvastatin (<20mg); Simvastatin (<40 mg)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-07
- Completion
- 2013-02
- Enrolment
- 136,966
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus, Type 2; Cardiovascular DiseaseInterventionRosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin +5 morePhaseNot recordedRegistry statusCompletedThe Rosuvastatin In TrAnsplant Recipients Study
NCT01524601 · start 2012-02
Registered record
- Registry ID
- NCT01524601
- Conditions
- Disorder Related to Renal Transplantation; Hypercholesterolemia
- Interventions
- Rosuvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-02
- Completion
- 2012-10
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDisorder Related to Renal Transplantation; HypercholesterolemiaInterventionRosuvastatinPhasePhase 4Registry statusCompletedEfficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT01551173 · start 2012-01
Registered record
- Registry ID
- NCT01551173
- Conditions
- Lipid Metabolism Disorders
- Interventions
- Fluvastatin sodium
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2013-05
- Enrolment
- 436
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLipid Metabolism DisordersInterventionFluvastatin sodiumPhasePhase 4Registry statusCompletedA Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
NCT01492361 · start 2011-11
Registered record
- Registry ID
- NCT01492361
- Conditions
- Cardiovascular Diseases
- Interventions
- AMR101; Placebo; Statin therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2018-05
- Enrolment
- 8,179
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular DiseasesInterventionAMR101; Placebo; Statin therapyPhasePhase 3Registry statusCompletedHigh Potency Statins and Acute Kidney Injury
NCT02518516 · start 2011-01
Registered record
- Registry ID
- NCT02518516
- Conditions
- Hypercholesterolemia
- Interventions
- Rosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin; Pravastatin; Lovastatin; Atorvastatin (<20mg); Simvastatin (<40 mg)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2011-01
- Completion
- 2013-01
- Enrolment
- 2,067,639
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypercholesterolemiaInterventionRosuvastatin (≥10 mg); Atorvastatin (≥20 mg); Simvastatin (≥40 mg); Fluvastatin +4 morePhaseNot recordedRegistry statusCompletedEvaluation of Patients With Statin Myopathy Using an N of 1 Trial Design
NCT01259791 · start 2010-09
Registered record
- Registry ID
- NCT01259791
- Conditions
- Statin Myopathy
- Interventions
- Individual-specific statin causing myopathy; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-09
- Completion
- 2013-08
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStatin MyopathyInterventionIndividual-specific statin causing myopathy; PlaceboPhaseNot applicableRegistry statusCompletedIntensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
NCT01293097 · start 2010-06
Registered record
- Registry ID
- NCT01293097
- Conditions
- Non-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris
- Interventions
- Atorvastatin; Statin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-06
- Completion
- 2011-10
- Enrolment
- 2,884
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina PectorisInterventionAtorvastatin; StatinPhasePhase 4Registry statusCompletedA Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C
NCT00814606 · start 2010-02
Registered record
- Registry ID
- NCT00814606
- Conditions
- Hepatitis C; Hepatitis C Virus
- Interventions
- Fluvastatin; Peginterferon alfa2a; ribavirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2010-02
- Completion
- 2010-10
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatitis C; Hepatitis C VirusInterventionFluvastatin; Peginterferon alfa2a; ribavirinPhasePhase 2Registry statusWithdrawnEffect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
NCT01047501 · start 2009-12
Registered record
- Registry ID
- NCT01047501
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-12
- Completion
- 2011-02
- Enrolment
- 702
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertriglyceridemiaInterventionAMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; PlaceboPhasePhase 3Registry statusCompletedEfficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
NCT01047683 · start 2009-12
Registered record
- Registry ID
- NCT01047683
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-12
- Completion
- 2011-07
- Enrolment
- 229
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertriglyceridemiaInterventionAMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day; PlaceboPhasePhase 3Registry statusCompletedEffects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
NCT00674297 · start 2008-05
Registered record
- Registry ID
- NCT00674297
- Conditions
- Antiphospholipid Syndrome
- Interventions
- Fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-05
- Completion
- 2013-02
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAntiphospholipid SyndromeInterventionFluvastatinPhasePhase 2Registry statusCompletedObservational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)
NCT00730132 · start 2008-01
Registered record
- Registry ID
- NCT00730132
- Conditions
- Coronary Heart Disease; Hypercholesterolemia
- Interventions
- Ezetimibe; Statin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2009-08
- Enrolment
- 712
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Heart Disease; HypercholesterolemiaInterventionEzetimibe; StatinPhaseNot recordedRegistry statusCompletedObservational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
NCT00673660 · start 2007-10
Registered record
- Registry ID
- NCT00673660
- Conditions
- Dyslipidemia
- Interventions
- Patient Compliance
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2009-10
- Enrolment
- 375
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDyslipidemiaInterventionPatient CompliancePhaseNot recordedRegistry statusCompletedFluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
NCT00487318 · start 2007-06
Registered record
- Registry ID
- NCT00487318
- Conditions
- Chronic Hepatitis C
- Interventions
- standard of care; fluvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2010-10
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis CInterventionstandard of care; fluvastatinPhasePhase 2Registry statusCompleted